Literature DB >> 12603693

Megadose transplantation of highly purified haploidentical stem cells: current results and future prospects.

Rupert Handgretinger1, Thomas Klingebiel, Peter Lang, Paul Gordon, Dietrich Niethammer.   

Abstract

The transplantation of megadoses of haploidentical hematopoietic stem cells is for a number of children with malignant or nonmalignant diseases the only curative approach. In order to prevent severe GvHD, the removal of T lymphocytes from the stem cell graft either by positive selection of CD34+ stem cells or by negative depletion of CD3+ T lymphocytes is necessary. We present the results obtained so far by CD34+ positive selection and discuss new techniques of graft engineering which might hopefully further improve the outcome of haploidentical stem cell transplantation.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12603693     DOI： 10.1034/j.1399-3046.7.s3.7.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN： 1397-3142


  6 in total

1.  Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Authors:  B L Tang; X Y Zhu; C C Zheng; H L Liu; L Q Geng; X B Wang; K Y Ding; W Yao; J Tong; K D Song; L Zhang; P Qiang; Z M Sun
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Haploidentical hematopoietic stem cell transplantation for nonresponders to immunosuppressive therapy against acquired severe aplastic anemia.

Authors:  L Liu; X Wang; S Jin; L Hao; Y Zhang; X Zhang; D Wu
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

3.  Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

Review 4.  Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?

Authors:  Gregory A Hale
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

5.  Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.

Authors:  Rebecca Epperly; Aimee C Talleur; Ying Li; Sarah Schell; MaCal Tuggle; Jean-Yves Métais; Sujuan Huang; Deqing Pei; Cheng Cheng; Renee Madden; Ewelina Mamcarz; Swati Naik; Amr Qudeimat; Akshay Sharma; Ashok Srinivasan; Ali Suliman; Stephen Gottschalk; Brandon M Triplett
Journal:  Transplant Cell Ther       Date:  2022-02-11

6.  Affinity-Bead-Mediated Enrichment of CD8+ Lymphocytes from Peripheral Blood Progenitor Cell Products Using Acoustophoresis.

Authors:  Anke Urbansky; Andreas Lenshof; Josefina Dykes; Thomas Laurell; Stefan Scheding
Journal:  Micromachines (Basel)       Date:  2016-06-09       Impact factor: 2.891
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.